Why Triglycerides, HDL, and AIP Still Predict Stents
Low LDL is important—but it’s not the whole story. In this episode, we’ll look at a study showing that even when LDL is below 70, your triglycerides, HDL, and AIP can still predict stents and heart attacks—and what you can do now to improve AIP.
🎧 ▶️ Press the play button below to listen in English.
🇨🇳 中文（简体）
LDL 很低当然重要，但它不是全部。今天我们用一项研究说明：即使 LDL 低于 70 mg/dL，甘油三酯、HDL 和 AIP 仍然能预测支架和心梗风险，并告诉你如何从现在开始改善 AIP。
请按下方的播放按钮收听。
🇪🇸 Spanish (Latinoamérica)
Tener el LDL bajo es importante, pero no lo es todo. En este audio veremos un estudio que muestra que, incluso con LDL por debajo de 70 mg/dL, los triglicéridos, el HDL y el AIP todavía pueden predecir stents e infartos—y qué puedes hacer hoy para mejorar tu AIP.
Presiona el botón de reproducir para escuchar.
I. Introduction: Low LDL-C Isn’t the Finish Line
For years, LDL-C (“bad cholesterol”) has been treated as the headline number for preventing atherosclerotic cardiovascular disease (ASCVD)—and for good reason. Lowering LDL-C reduces risk. But many people quietly absorb a second (and dangerous) conclusion: if my LDL-C is “perfect,” I’m safe.
The problem is that real-world cardiology keeps showing something uncomfortable: patients can hit the LDL-C goal and still suffer acute coronary syndrome (ACS)—and some still end up needing percutaneous coronary intervention (PCI), the procedure where cardiologists open a narrowed coronary artery and often place a stent.
In fact, the study we’re discussing focused only on people who already had “optimal” LDL-C: every single patient in the cohort had LDL-C below 1.8 mmol/L (below 70 mg/dL)—yet they presented with ACS and underwent PCI anyway. [Wang et al. 2023 The predictive value of atherogenic index of plasma for cardiovascular outcomes in patients with acute coronary syndrome undergoing percutaneous coronary intervention with LDL-C below 1.8mmol/L]
That’s why this paper matters. It doesn’t argue against LDL lowering. It argues against LDL-only thinking.
The cautionary tale: “Optimal LDL” can hide ongoing risk
In this retrospective cohort of 1,133 ACS patients with LDL-C <1.8 mmol/L who underwent PCI, the investigators asked a practical question: When LDL-C is already at goal, what still predicts trouble ahead?
Their answer was the Atherogenic Index of Plasma (AIP), a simple number calculated from a standard lipid panel:
- AIP = log (Triglycerides / HDL-C)
AIP matters because it reflects the “metabolic” side of lipid risk—especially the pattern of higher triglycerides (TG) and lower HDL-C, which often travels with insulin resistance and smaller, denser, more atherogenic lipoproteins.
The Big Finding
Over a median follow-up of 26 months, people with higher AIP had more adverse cardiovascular outcomes than those with lower AIP. Specifically:
- MACCE (major adverse cardiovascular and cerebrovascular events) occurred more often in the high-AIP group (9.6% vs 6.0%).
- The difference was driven mainly by unplanned repeat revascularization—meaning they needed another procedure to restore blood flow (7.6% vs 4.6%).
- Even after adjusting for multiple risk factors, higher AIP still predicted higher risk.
So the message is not subtle: LDL-C can be “great,” yet the patient can still be on a path toward more stents, more procedures, and greater danger—if the TG/HDL pattern remains unhealthy.
The lesson of the article (and why you should care before a cardiologist does)
If you’re reading this because you’re trying to prevent a heart attack—or prevent a second one—here’s the key lesson that this study supports:
Don’t wait to have the PCI before you improve your AIP; improve your AIP now to prevent a PCI.
In other words, LDL-C is necessary, but it is not the end-all, be-all. The residual risk—the risk that remains after LDL is controlled—often lives in triglycerides and HDL, and AIP is a convenient way to bring that risk into focus.
The authors even say the quiet part out loud: despite achieving recommended LDL-C levels, residual cardiovascular risk persists, especially in patients with atherogenic dyslipidemia (higher TG or low HDL-C).
This article will use the study as a practical warning: you can “win” on LDL-C and still lose the war—unless you also address the lipid pattern that AIP captures.
II. When LDL-C Can Be Below 1.8 mmol/L—But Your Risk Can Still Be High
Hitting an LDL-C target—below 1.8 mmol/L (below 70 mg/dL)—is often treated like the finish line. But LDL-C is only one piece of lipid risk. This study is important precisely because it looked at a group where LDL-C was already “excellent,” yet these patients still presented with acute coronary syndrome (ACS) and underwent PCI.
So how does that happen? Here are the most common real-world scenarios in which LDL-C can be low while ASCVD risk remains high.
A. LDL-C can be “perfect” because medication is doing its job
Many people reach LDL-C <1.8 mmol/L because they are on intensive therapy—especially after an event like ACS.
In this study:
- Nearly everyone was discharged on a statin (about 99% in both AIP groups).
- Yet outcomes still differed by AIP, not by LDL-C.
Translation: lowering LDL-C is necessary—but it does not automatically erase risk coming from triglycerides, HDL, insulin resistance, inflammation, or plaque biology.
B. LDL-C can be low in the setting of “atherogenic dyslipidemia”
A common pattern in insulin resistance and metabolic syndrome is:
- Higher triglycerides
- Lower HDL-C
- More small, dense LDL particles
That pattern can exist even when LDL-C is low.
This paper explicitly frames this as the “residual risk” problem: even with LDL-C controlled to guideline targets, residual cardiovascular risk persists, especially in patients with higher TG or lower HDL-C.
And that’s exactly what AIP captures:
- AIP = log(TG/HDL-C)
- It correlates with lipoprotein particle size/density and is considered a marker of “plasma atherogenicity.”
In the baseline data, the high-AIP group had the classic metabolic pattern:
- HDL-C was lower (about 0.9 vs 1.1 mmol/L)
- TG was higher (median 1.8 vs 0.9 mmol/L)
- LDL-C, importantly, was essentially the same in both groups (around 1.5 mmol/L).
That’s the whole point: LDL-C didn’t separate risk here. TG and HDL (and therefore AIP) did.
C. LDL-C can be low because cholesterol mass isn’t the same as particle danger
LDL-C measures the amount of cholesterol carried inside LDL particles—not necessarily:
- How many particles are present (particle number)
- How “damaging” they are (oxidation-prone, small/dense, inflammatory context)
The authors emphasize that LDL particles vary in size and properties, and that smaller, denser particles are more susceptible to oxidation and more atherogenic.
When TG is elevated, LDL particles tend to become smaller and denser—one of the mechanisms the paper proposes for AIP’s prediction of worse outcomes.
So LDL-C can look “low” while the atherogenic machinery—particle remodeling, oxidation, plaque vulnerability—keeps running.
D. LDL-C can be low in people with diabetes, prediabetes, or insulin resistance
Insulin resistance often drives:
- Higher TG
- Lower HDL
- Higher AIP
- More cardiometabolic risk
In this cohort, the high-AIP group had:
- More diabetes (about 46.7% vs 38.9%)
- Higher HbA1c and fasting glucose
And the paper notes that AIP is strongly associated with insulin resistance and that insulin resistance raises susceptibility to cardiovascular events.
So it’s entirely possible to “win” LDL-C while still losing on the deeper metabolic drivers of plaque progression.
E. LDL-C can be low because the patient is already in secondary prevention
A major reason LDL-C is low in some patients is simple: they already have coronary disease, and clinicians have already pushed LDL-C down hard.
This study population wasn’t “healthy people with low LDL.” These were people with:
- Active ACS
- Undergoing PCI
- Many have had prior MI or prior PCI.
That matters because coronary disease is not just about LDL level today—it’s about:
- Plaque burden accumulated over decades
- Plaque instability
- Endothelial dysfunction
- Thrombosis risk
- Residual lipid and inflammatory risk after LDL is controlled
Bottom line of Section II
LDL-C below 1.8 mmol/L can happen for many reasons, especially medication and secondary prevention. But the key takeaway from this study is that when LDL-C is already controlled, risk doesn’t disappear. It shifts.
And in this paper, that “hidden” risk was strongly signaled by AIP, i.e., the TG/HDL relationship—because the high-AIP group had more MACCE and more repeat revascularization despite having the same LDL-C as the low-AIP group.
III. What Are PCI and Stents—and How Long Are They “Good For”?
If LDL-C is the lab number people obsess over, PCI is the real-world moment when the disease becomes undeniable.
Because in this study, every patient already had LDL-C below 1.8 mmol/L (70 mg/dL)—yet they still developed acute coronary syndrome (ACS) and still required PCI.
That fact alone should shake the idea that “low LDL means I’m safe.”
To understand the warning in this paper, it helps to understand what PCI and stenting actually do—and what they don’t do.
A. What is PCI?
PCI (Percutaneous Coronary Intervention) is a catheter-based procedure used to restore blood flow in a narrowed or blocked coronary artery.
In plain language:
- A cardiologist threads a thin tube (catheter) through an artery—often from the wrist or groin—up to the heart.
- A balloon may be inflated to widen the blockage.
- A stent is often placed to keep the artery open.
This procedure is commonly done during or shortly after:
- ST-elevation myocardial infarction (STEMI)
- Non–ST-elevation myocardial infarction (NSTEMI)
- Unstable angina
In the study population, most patients had unstable angina, with smaller groups having STEMI and NSTEMI.
B. What is a coronary stent?
A stent is a small metal mesh tube placed inside the artery to prevent it from narrowing again after balloon dilation.
Most modern stents are drug-eluting stents (DES), which slowly release medication to reduce scar tissue and lower the risk of the artery re-narrowing (restenosis).
After PCI, patients are usually placed on dual antiplatelet therapy (DAPT) to prevent clot formation within the stent.
In this paper, the standard approach described was aspirin plus ticagrelor for at least 12 months, with variations based on bleeding risk and procedural complexity.
C. What PCI and stenting actually accomplish—and what they do not
PCI treats a blockage. It does not “cure” coronary artery disease.
Think of coronary disease like rust in plumbing:
- PCI opens one narrowed segment.
- But the biological process that created the plaque—metabolic dysfunction, inflammation, insulin resistance, atherogenic lipoproteins—can continue.
That’s why cardiology has a term called residual risk: even after LDL is controlled and the artery is opened, events can still occur.
The authors explicitly describe this phenomenon: even when LDL-C goals are met with intensive lipid-lowering therapy, some patients remain at increased risk of recurrent cardiovascular events, implying LDL-C alone isn’t enough.
D. How long are stents “good for”?
This is the part many patients don’t realize: a stent is not a lifetime guarantee.
There are two main ways a stented patient can end up back in the cath lab:
- In-stent restenosis
- The artery narrows again at the stent site, often due to tissue growth/scarring (less common with modern DES than older stents).
- Progression of plaque elsewhere
- New plaques grow or rupture in other segments of the same artery or in different coronary arteries.
In real practice, both lead to the outcome called repeat revascularization—meaning the person needs another procedure to restore blood flow.
And this is exactly where the study hits hardest.
E. The study’s “stent reality check”: repeat procedures were common, and AIP predicted them
The primary composite outcome in this paper was MACCE (major adverse cardiovascular and cerebrovascular events), including death, nonfatal MI, stroke, and unplanned repeat revascularization.
In this study, unplanned repeat revascularization was defined as being driven by angina or ischemia, meaning patients typically had symptoms again that raised alarm—often crushing chest pressure or pain (sometimes spreading to the arm, neck, or jaw), cold sweating (“breaking out in a sweat”), and shortness of breath.
These episodes aren’t just inconvenient—they’re frightening, disruptive, and often urgent—exactly the kind of experience you want to prevent by fixing the metabolic “residual risk” early.
Over a median of 26 months, there were:
- 88 MACCE events
- Including 69 unplanned repeat revascularizations
That means repeat procedures were the dominant “bad outcome” in this cohort.
And when patients were split into low vs high AIP:
- MACCE was higher in the high AIP group (9.6% vs 6.0%)
- This difference was mainly driven by unplanned repeat revascularization (7.6% vs 4.6%)
Even after adjusting for multiple factors, higher AIP still predicted worse outcomes.
So if you want a simple takeaway about “how long stents last,” this study offers a blunt answer:
- In a little over two years, repeat procedures were common—and the people with worse TG/HDL patterns were the ones more likely to need them.
Key point of Section III
PCI can be lifesaving, and stents can restore blood flow fast. But they do not erase the disease process.
This paper is essentially saying: even after a stent, even with LDL-C already below 70 mg/dL, the metabolic lipid pattern captured by AIP still predicts who is likely to return for more revascularization.
Don’t wait for a PCI to improve your AIP—improve it now to prevent a PCI.
IV. The Study at a Glance (Why This Paper Matters)
To make the message concrete, let’s name the paper and summarize exactly what the researchers did.
A. What question were they trying to answer?
The authors point out a clinical gap: even when ACS patients reach the LDL-C goal recommended by guidelines, some still have bad outcomes. Their key question was:
Does AIP (atherogenic index of plasma) still predict future cardiovascular events in ACS patients who underwent PCI—even when LDL-C is already below 1.8 mmol/L?
B. Who was studied?
Study type: retrospective, single-center observational cohort
Final cohort:1,133 patients
- All had acute coronary syndrome (ACS)
- All underwent PCI
- All had LDL-C < 1.8 mmol/L
This is the key point: the study was not about people with high LDL who “obviously” needed lipid work. It was about people who—on paper—already looked like they had “good LDL.”
C. What is AIP, and how did they use it?
- AIP definition: calculated as log (TG/HDL-C)
- Participants were split into two groups based on the median AIP value. The predictive value of atherog…
- In this cohort, the median AIP cut point was about 0.11 (used to define lower vs higher AIP).
D. What outcomes did they track?
The primary endpoint was MACCE, a composite outcome that included:
- All-cause death
- Nonfatal myocardial infarction
- Ischemic stroke
- Unplanned repeat revascularization (repeat PCI or bypass prompted by angina/ischemia)
Follow-up was done through phone calls or outpatient visits until December 31, 2020, or death.
E. Why is this study so useful?
Because it isolates a very specific—and very common—clinical situation:
LDL-C is already at goal but the patient still had ACS and needed PCI.
What predicts who does worse afterward?
Their finding: AIP matters, even in the “low LDL-C” world.
V. Key Findings: Low LDL-C Did Not Mean Low Risk
This study is powerful because it removes the usual excuse: “Well, of course they had events—the LDL was high.” Not here. LDL-C was already below 1.8 mmol/L (70 mg/dL) in everyone.
Yet outcomes still differed—meaning something else was driving risk. That “something else” was the lipid pattern captured by AIP (log[TG/HDL-C]).
A. The big picture: AIP predicted worse outcomes after PCI
The authors followed 1,133 ACS patients after PCI for a median of 26 months. Over that period:
- 88 patients experienced MACCE (major adverse cardiovascular and cerebrovascular events).
- The MACCE composite included death, MI, stroke, and unplanned repeat revascularization.
When patients were divided into low AIP vs high AIP groups (split at the median), the high AIP group consistently did worse.
B. The headline numbers: MACCE was higher with higher AIP
Over follow-up:
- MACCE incidence
- High AIP: 9.6%
- Low AIP: 6.0%
- Difference significant by log-rank testing
This is the key clinical idea: two people can have the same “excellent” LDL-C, yet the one with a worse TG/HDL pattern is more likely to have major adverse outcomes.
C. The main driver: repeat procedures (repeat revascularization)
The most important—and most actionable—finding is what drove the MACCE difference:
- Unplanned repeat revascularization
- High AIP: 7.6%
- Low AIP: 4.6% The predictive value of atherog…
And in the overall cohort, repeat revascularization made up most of the “bad outcomes”:
- 69 unplanned repeat revascularizations out of 88 MACCE events.
Even after a successful stent, the people with worse AIP were more likely to come back and need another procedure, because the disease process was still active.
D. AIP predicted risk even after adjusting for confounders
The authors didn’t just report raw event rates—they also adjusted for many clinical variables (age, sex, BMI, hypertension, diabetes, prior MI/stroke, LDL-C, total cholesterol, HbA1c, uric acid, and more).
After adjustment, AIP still predicted MACCE:
- High vs low AIP was associated with increased MACCE risk (adjusted hazard ratio ~1.62, with confidence intervals excluding no effect).
- AIP also remained significant when analyzed as a continuous variable (risk rising as AIP rises).
For repeat revascularization specifically, the adjusted risk was also higher in the high AIP group (HR ~1.74).
E. LDL-C did not explain the difference
This is what makes the study so useful as a cautionary tale:
- LDL-C was essentially the same in both groups (about 1.5 mmol/L in each).
- The separating variables were HDL-C and TG:
- HDL-C is lower in the high AIP group.
- TG is higher in the high AIP group
So the study is basically demonstrating “LDL success” with “metabolic failure”—and showing that the metabolic side predicts who does worse.
F. The practical interpretation
If a person walks away from this paper with one lesson, it should be this:
- LDL-C is crucial, but it is not the whole story.
- If your TG is high and your HDL is low, you may still carry a substantial atherogenic burden—even when LDL-C looks “ideal.”
- And in this cohort of already-low LDL-C patients, that pattern predicted more repeat procedures after stenting.
Don’t wait to have the PCI before you improve your AIP; improve your AIP now to prevent a PCI.
VI. How Common Is ACS or PCI Despite “Low LDL”—and What This Study Can (and Can’t) Tell Us
Many people consider LDL-C <1.8 mmol/L (70 mg/dL) a protective shield. This study shows—very clearly—that it isn’t.
But it’s important to be precise about what the paper can honestly claim about “incidence,” because this was not a population survey. It was a hospital-based cohort of people who had already presented with ACS and underwent PCI.
A. The clearest fact: ACS + PCI happened in 1,133 people who already met the LDL goal
The simplest and most striking “incidence” statement from this paper is this:
- The researchers identified 1,133 patients who:
- had acute coronary syndrome (ACS)
- underwent PCI
- and had LDL-C <1.8 mmol/L
The predictive value of atherog…
So, regardless of what their LDL number looked like on paper, these people still progressed to the kind of coronary event that lands you in a cath lab.
Low LDL-C does not guarantee you won’t have ACS, and it does not guarantee you won’t need a stent.
While the study can’t prove lifestyle causality, it reinforces that “LDL-only” isn’t enough—TG/HDL biology still predicts events, and that’s exactly the terrain where lifestyle usually has the biggest impact.
B. What this study does not provide: population-wide incidence rates
Because the study began with patients who already had ACS and PCI, it cannot tell us:
- What percentage of all low-LDL adults will have ACS
- The community incidence of stents among low-LDL people
- The risk of first-time ACS in the general population with LDL <70
What the study can legitimately say is more clinically relevant anyway:
- Even among patients with LDL already at target, outcomes vary
- And that variation is strongly linked to AIP (the TG/HDL pattern).
C. The “repeat PCI” incidence is directly measured—and it’s the part readers should fear most
Where this study does give clean incidence numbers is what happened after the PCI.
Over a median of 26 months, the cohort experienced:
- 88 MACCE events
- Including 69 unplanned repeat revascularizations
That means repeat procedures were not rare—they were the dominant adverse outcome in this dataset.
And when divided by AIP level:
- Repeat revascularization
- High AIP: 7.6%
- Low AIP: 4.6% The predictive value of atherog…
So the actionable “incidence” message becomes:
In low-LDL patients who already needed a stent, those with worse AIP were much more likely to need another revascularization within roughly two years.
D. Why this matters even if you’ve never had a stent
Many readers will think: “Okay, but those were already ACS patients.”
That’s exactly why the study is a warning. It highlights the residual-risk concept:
- LDL-C can be controlled
- Yet the atherogenic process can continue—especially in people with the TG/HDL pattern captured by AIP.
So while this paper doesn’t provide population incidence, it provides something more personal and urgent:
- If your metabolism pushes TG up and HDL down, you can still have major coronary disease even with low LDL
- And if you already have CAD, that pattern predicts more procedures even after LDL is “optimized.”
VII. The AIP Calculator (Interactive Tool + Guidepost Values)
One reason this study is so practical is that it uses a marker you can calculate from a standard lipid panel—no advanced testing required.
The marker is the Atherogenic Index of Plasma (AIP), and in this ACS + PCI population with LDL-C already below 1.8 mmol/L, AIP still predicted worse outcomes.
A. What is AIP?
AIP = Atherogenic Index of Plasma
It is calculated as:
AIP = log (Triglycerides / HDL-C) The predictive value of atherog…
This study used that definition and then split patients into low vs high AIP groups based on the median AIP value.
B. Calculator inputs
From the fasting lipid panel (or non-fasting, if that’s all you have, but fasting is cleaner):
- Triglycerides (TG)
- HDL cholesterol (HDL-C)
Important: AIP is best calculated when TG and HDL-C are in the same units.
Most research papers calculate AIP using mmol/L values (as this study does).
If you have mg/dL, there is an option in the calculator.
Atherogenic Index (AIP) Calculator
Calculates AIP = log10(Triglycerides ÷ HDL) using mmol/L internally.
C. AIP Guidepost values
AIP is best treated as a risk signal, not a diagnosis.
Commonly used guideposts:
- AIP < 0.11 → Lower risk
- AIP 0.11 to 0.21 → Intermediate risk
- AIP > 0.21 → Higher risk
This study’s median cut point for splitting groups was approximately 0.11, meaning “high AIP” began at ≥0.11 in their cohort.
And importantly, the authors found that higher AIP predicted worse outcomes after PCI, even after adjusting for multiple confounders like age, sex, ethnicity, etc.
In the Wang et al. study,
- In ACS patients with already “optimal” LDL, the group with AIP ≥ 0.11 had:
- Higher MACCE (9.6% vs 6.0%)
- Higher repeat revascularization (7.6% vs 4.6%)
If your AIP is drifting upward—especially above ~0.11—don’t ignore it just because your LDL looks great.
VIII. How to Improve Your AIP (Do This Before You Need a Stent)
If AIP is high, the goal isn’t to “treat a number.” The goal is to change the metabolic environment that drives plaque growth, plaque instability, and repeat procedures.
This matters because in the study, the group with higher AIP—despite having LDL-C already below 1.8 mmol/L—had more major adverse events and more unplanned repeat revascularization after PCI.
So here’s the practical part: how do you bring AIP down?
AIP improves when triglycerides go down, and HDL rises (or improves functionally)—and those shifts usually happen when insulin resistance improves.
A. The fastest lever: lower triglycerides (TG)
For most people, triglycerides respond quickly—often within weeks—when you make the right changes.
1) Cut sugar and refined starch first
These are the biggest TG drivers for many people:
- sugary drinks, desserts, candy
- white bread, rice, pasta, crackers
- frequent snacking on carbs
A simple rule that works:
- If it spikes your blood sugar, it often spikes your TG downstream.
2) Reduce “liquid carbs” and alcohol
Alcohol is a classic triglyceride raiser in many people, especially when combined with carbs.
If TG is high:
- Cut back on alcohol
- Avoid alcohol + sweets as a combo
3) Don’t be fooled by “low fat.”
A low-fat diet can still produce high TG if it is high in starch and sugar.
4) Prioritize protein and fiber
In meals, aim for:
- a solid protein anchor (fish, eggs, poultry, lean meat, tofu)
- fiber-rich carbs (vegetables, legumes, whole foods)
- avoid “naked carbs” (carbs by themselves)
5) Move after meals
Even a 10–20 minute walk after eating can lower post-meal glucose and reduce the metabolic pressure that worsens TG over time.
B. Build HDL the way that matters (not by chasing a supplement)
HDL is complicated. The goal isn’t “raise HDL at all costs.” The goal is to improve the lifestyle factors that make HDL work better.
1) Exercise is the most reliable HDL booster
- brisk walking, cycling, swimming
- resistance training (very helpful for insulin sensitivity)
If you only do one thing:
- Do consistent exercise, 4–6 days/week
2) Stop smoking
Smoking tends to lower HDL and damages the vascular lining.
3) Improve sleep and stress
Chronic sleep deprivation and stress hormones can worsen insulin resistance, and that often worsens TG/HDL patterns.
C. Fix insulin resistance (because AIP often reflects it)
The paper discusses that elevated AIP is associated with insulin resistance, and insulin resistance is linked with higher cardiovascular risk.
So if your AIP is high, assume insulin resistance may be part of the story until proven otherwise.
High-impact insulin-sensitivity strategies:
- reduce central/visceral fat
- strength training (build muscle = improve glucose disposal)
- avoid frequent high-carb snacking
- time your carbs around activity rather than late-night sedentary eating
- consider tracking: fasting glucose, A1c, fasting insulin (if available)
D. If you’ve already had a PCI, why is improving AIP urgent
This study’s warning is not hypothetical. In these low-LDL ACS patients after PCI, the higher AIP group had more unplanned repeat revascularization.
That means:
- A stent does not end the disease.
- If the metabolic lipid pattern stays unhealthy, the person is more likely to need another intervention.
So after PCI, think of AIP as one more “dashboard gauge”:
- LDL is one gauge
- AIP is another
- You want both moving in the right direction
E. A simple “AIP Improvement Checklist.”
If you want a short plan you can actually follow:
- Eliminate sugary drinks + desserts for 30 days
- Make every meal protein-first
- Walk 10–20 minutes after your biggest meal
- Lift weights (or do resistance work) 2–4x/week
- Limit alcohol (especially alcohol + carbs)
- Recheck TG, HDL, and AIP in 6–12 weeks
Section Summary
LDL-C matters—but the message of this study is that AIP still predicts trouble even when LDL is already “optimized.” The predictive value of atherog…
So don’t wait until the day you hear:
- “You need a cath.”
- “You need a stent.”
- “You need another procedure.”
Improve your AIP now—so you never need the PCI in the first place.
Don’t Get Sick!
Medically Reviewed by Dr. Jesse Santiano, MD
Dr. Santiano is a retired internist and emergency physician with extensive clinical experience in metabolic health, cardiovascular prevention, and lifestyle medicine. He reviews all medical content on this site to ensure accuracy, clarity, and safe application for readers. This article is for educational purposes and is not a substitute for personal medical care.
💡 Support This Work
Creating well-researched articles, maintaining this website, and keeping the information free takes time and resources.
If you found this article helpful, please consider donating to support the mission of empowering people to live healthier, longer lives, without relying on medications.
🙏 Every contribution, big or small, truly makes a difference. Thank you for your support!
Follow me on Facebook, Gab, Twitter (formerly known as X), and Telegram.
Related:
- AIP Predicts Heart Attack Risk In Younger Adults
- 15 Diseases Predicted By The Atherogenic Index Of Plasma
- AIP and Cardiovascular and Atherosclerotic Risk: A Simple TG/HDL Number That Tracks Artery Health
- Atherogenic Index (AIP): Meaning, Clinical Uses and Calculator
- Small Dense LDL: What It Means And How To Improve It
- ApoB vs LDL Cholesterol: Which Predicts Heart Attacks Better
- LDL Particle Number Explained: A Better Marker Than LDL Cholesterol
- TG/HDL Ratio Explained: What It Means and How to Improve It
- HDL Function Explained: Good vs Bad HDL
- High Triglycerides: Causes, Dangers, And How To Lower
- Mastering Diabetes: Prevent Hypoglycemia with Smart Medication Adjustments
- 102 Easy Ways to Lower Post-Prandial Blood Sugar Without Meds
- The Simple Way To Keep Blood Sugar Low: Breakfast
- Meal Timing: A Practical Guide To Weight Loss And Better Health
- 18 Powerful Strategies To Prevent Blood Sugar Spikes During The Holidays
- Applying The Best Behavior Change Techniques At Home For Better Health
- A Toolbox of Strategies to Prevent Blood Sugar Spikes When Eating High-Glycemic- Index Foods
- The Blood Sugar Lowering and Metabolic Effects of Vinegar
- Ways to Lower After-Meal Blood Sugar when Eating White Bread
- A High-Protein Breakfast Can Lower Blood Sugar the Whole Day
- Eating rather than skipping breakfast results in lower blood sugars the whole day
References:
- Wang Y, Wang S, Sun S, Li F, Zhao W, Yang H, Wu X. The predictive value of atherogenic index of plasma for cardiovascular outcomes in patients with acute coronary syndrome undergoing percutaneous coronary intervention with LDL-C below 1.8mmol/L. Cardiovasc Diabetol. 2023 Jun 26;22(1):150. doi: 10.1186/s12933-023-01888-3. PMID: 37365588; PMCID: PMC10294439. https://pubmed.ncbi.nlm.nih.gov/37365588/
Disclaimer:
This article is for educational purposes and is not a substitute for professional medical advice, diagnosis, or treatment. Always consult your physician before making health decisions based on the TyG Index or other biomarkers.
© 2018 – 2025 Asclepiades Medicine, LLC. All Rights Reserved
DrJesseSantiano.com does not provide medical advice, diagnosis, or treatment
As an Amazon Associate, I earn from qualifying purchases
Discover more from Don't Get Sick!
Subscribe to get the latest posts sent to your email.